IMPACT Articles

CHICAGO, IL USA (UroToday.com) - Presented by Pieczonka CM,¹ Concepcion RS,² Tutrone RF,³ Penson DF,⁴ Bailen JL,⁵ Olsson CA,⁶ Forrest JB,⁷ Kassabian V,⁸ Mehlhaff BA,⁹ Shore ND,¹¹ Lance RS,¹¹ Tyler RC,¹² Sandler A,¹² McCoy C,¹² Whitmore JB,¹² and Cooperberg MR¹³ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

BERKELEY, CA (UroToday.com) - The treatment of metastatic castrate resistant prostate cancer (mCRPC) has changed drastically over the past few years with the emergence of several new therapies.

CHICAGO, IL USA (UroToday.com) - Presented by Celestia S. Higano,¹ Andrew J. Armstrong,² Matthew R. Cooperberg,³ Philip W. Kantoff,⁴ James L. Bailen,⁵ Raoul S. Concepcion,⁶ Vahan Kassabian,⁷ Shaker R. Dakhil,⁸ Steven E. Finkelstein,⁹ Jeffrey L. Vacirca,¹⁰ Robert M. Rifkin,¹¹ Andrew Sandler,¹² Candice McCoy,¹² James B. Whitmore,¹² Robert C.Tyler,¹² and Oliver Sartor¹³ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

SAN DIEGO, CA USA (UroToday.com) - Presented by E. David Crawford, MD,¹ Adam S. Kibel, MD,² and Neal D.Shore, MD, FAC ³ at the American Urological Association (AUA) Annual Meeting - May 4 - 8, 2013 - San Diego Convention Center - San Diego, California USA

SAN DIEGO, CA USA (UroToday.com) - Presented by Matthew R. Cooperberg, MD,¹ Oliver Sartor, MD,² Christopher Pieczonka, MD,³ Raoul S. Concepcion, MD, FACS,⁴ Vahan Kassabian, MD,⁵ Ronald Tutrone, MD, FACS, CPI,⁶ James Bailen, MD,⁷ Neal Shore, MD, FACS,⁸ Lawrence Karsh, MD, FACS,⁹ Bernard Hertzman, MD,¹⁰ David Penson, MD, MPH,¹¹ Candice Mccoy, MD,¹² Andrew Sandler, MD,¹² Robert Tyler, PhD,¹² James Whitmore, PhD,¹² and Celestia S. Higano, MD¹³ at the American Urological Association (AUA) Annual Meeting - May 4 - 8, 2013 - San Diego Convention Center - San Diego, California USA

To characterize the current landscape and future directions of academic benign prostatic hyperplasia (BPH) by using bibliometric analysis.

We used the Web of Science Core CollectionTM to conduct a bibliometric analysis of leading BPH articles.

To evaluate the impact of Gallium-68 [68Ga] labeled prostate specific membrane antigen (PSMA) positron emission tomography (PET)/X-ray computed tomography (CT) compared with conventional imaging on staging and clinical management of men evaluated for primary prostate cancer (PCa).

Overactive bladder (OAB) is a common condition that has a significant impact on patients' health-related quality of life and is associated with a substantial economic burden to healthcare systems. OnabotulinumtoxinA has a well-established efficacy and safety profile as a treatment for OAB; however, the economic impact of using onabotulinumtoxinA has not been well described.

Recent trials have shown that the addition of external beam radiotherapy (EBRT) to androgen deprivation therapy (ADT) improves survival among men with locally advanced prostate cancer.

To examine the potential impact of these trials on changes in clinical practice and life-years saved.

ORLANDO, FL, USA (UroToday.com) - The Phase 3 IMPACT study showed significant improvement in overall survival with sipuleucel-T immunotherapy. The PROCEED trial is an ongoing Phase 4 registry enrolling patients receiving sipuleucel-T in the real-world setting. Enrollment has no restriction on whether docetaxel has been used to treat.

68Gallium prostate-specific membrane antigen positron emission tomography (68Ga-PSMA PET) is an emerging imaging modality for assessment of prostate cancer. Recent studies show promising results regarding its ability to detect recurrent or metastatic prostate cancer superior to that of conventional imaging modalities.

To evaluate the impact of nocturia on patients' quality of life and healthcare resource utilisation (HRU) compared with overactive bladder (OAB) and benign prostatic hyperplasia (BPH).

Data were drawn from a multinational (France, Germany, Spain, UK and US) survey of physician and patient-reported outcomes.

Radical cystectomy (RC) for the management of muscle-invasive bladder cancer remains a morbid procedure with high rates of perioperative complications. The role of pre-operative immuno-nutritional supplementation (Pre-INS) in improving post-RC outcomes is promising and needs further validation.

Prostate-specific membrane antigen (PSMA) is overexpressed in the neovasculature of renal cell carcinoma (RCC). However, there remains limited evidence regarding the use of PSMA positron emission tomography/computed tomography (PET/CT) in RCC.

To determine the estimated budget impact to practices that incorporate blue light cystoscopy (BLC) with hexaminolevulinate HCl (HAL) for the surveillance of non-muscle-invasive bladder cancer (NMIBC) in the clinic setting.

With the introduction of advanced technologies in the clinic setting such as HAL, further cost comparative research is needed to justify HAL as a high value option.

BERKELEY, CA (UroToday.com) - Presented by James L. Gulley, MD, PhD, FACP

BERKELEY, CA USA (UroToday.com) - Presented by Leonard Gomella, MD, Clinical Director Jefferson Kimmel Cancer Center Network, Philadelphia, PA USA